Replies to post #181967 on Biotech Values

[DewDiligence]

So the FDA does agree that triglyceride-reducing drugs also reduce cardiovascular risks, but only in the over 500 range?

The way you phrased the question could lead to ambiguity. FDA thinks the clinical benefit from lowering triglycerides is clear in the 500+ range and that it remains to be proven in the sub-500 range.

[DewDiligence]

ACST phase-2 trial hits primary endpoint, but stock declines:

http://finance.yahoo.com/news/acasti-reports-successful-capre-r-120000479.html

Guilt by association with AMRN could be a factor in the sell-off here.

p.s. It’s curious that the quoted individual in the PR is not an executive officer, but rather is BoD member, Harlan Waksal.